Abstracts tagged "systemic lupus erythematosus (SLE) and treatment"

Abstract Number: 2623 • 2014 ACR/ARHP Annual Meeting
Treatment Patterns and Resource Utilization of Systemic Lupus Erythematosus Patients Newly Initiating Standard of Care: United States Commercial and Medicare Supplemental Claims Analysis
Shonda A Foster¹, Emily Durden², Brett Maiese², Sarah Al Sawah¹ and Kathleen Solotkin¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Truven Health Analytics, Bethesda, MD
Background/Purpose: Currently, there is not a standard treatment algorithm for the management of Systemic Lupus Erythematosus (SLE); however, there are medications that may be considered…
Abstract Number: 2530 • 2013 ACR/ARHP Annual Meeting
Sustained Improvements In Health-Related Quality Of Life In Patients With Systemic Lupus Erythematosus following Epratuzumab Treament: Results from a Phase IIb Trial and Its Open-Label Extension
Vibeke Strand¹, Joan T. Merrill², Enkeleida Nikaï³, Brian Kilgallen⁴, Antoine Regnault⁵ and Caroline Gordon⁶, ¹Stanford University, Palo Alto, CA, ²Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³UCB Pharma, Brussels, Belgium, ⁴UCB Pharma, Raleigh, NC, ⁵Mapi HEOR & Strategic Market Access, Lyon, France, ⁶Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. Improvements in health-related quality of life (HRQoL) with epratuzumab in patients with systemic lupus erythematosus (SLE) have…
Abstract Number: 1807 • 2013 ACR/ARHP Annual Meeting
Do We Know How and When To Taper and Stop In Immunosuppressants In Lupus Patients?
Zahi Touma¹, Murray B. Urowitz², Dominique Ibanez² and Dafna D. Gladman², ¹Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: After achieving low disease activity or remission, immunosuppressant therapies might be stopped in lupus patients, but information on whether and how this should be…
Abstract Number: 1738 • 2013 ACR/ARHP Annual Meeting
Epratuzumab Maintains Improvements In Disease Activity For Over 2 Years In Patients With Moderate-To-Severe Systemic Lupus Erythematosus: Results From An Open-Label Long-Term Extension Study
Megan E. B. Clowse¹, Frederic Houssiau², Michelle A. Petri³, Brian Kilgallen⁴, Kenneth Kalunian⁵, Vibeke Strand⁶, Sabine Bongardt⁷, Caroline Gordon⁸ and Daniel J. Wallace⁹, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴UCB Pharma, Smyrna, GA, ⁵UCSD School of Medicine, La Jolla, CA, ⁶Stanford University, Palo Alto, CA, ⁷UCB Pharma, Brussels, Belgium, ⁸Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁹Rheumatology, Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. In EMBLEMTM (dose-ranging phase IIb study), epratuzumab produced clinically relevant improvements in disease activity in patients…
Abstract Number: 1739 • 2013 ACR/ARHP Annual Meeting
Sustained British Isles Lupus Assessment Group-Measured Improvement In Moderately-and-Severely Affected Body Systems In Patients With Systemic Lupus Erythematosus By Epratuzumab: Results From An Open-Label Extension Study
Kenneth Kalunian¹, Megan E. B. Clowse², Frederic Houssiau³, Michelle A. Petri⁴, Brian Kilgallen⁵, Caroline Gordon⁶, Vibeke Strand⁷, Sabine Bongardt⁸ and Daniel J. Wallace⁹, ¹UCSD School of Medicine, La Jolla, CA, ²Rheumatology, Duke University Medical Center, Durham, NC, ³Department of Rheumatology, Université catholique de Louvain, Brussels, Belgium, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵UCB Pharma, Raleigh, NC, ⁶Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ⁷Stanford University, Palo Alto, CA, ⁸UCB Pharma, Brussels, Belgium, ⁹Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Epratuzumab is a monoclonal antibody targeting CD22. In EMBLEMTM (a dose-ranging phase IIb study), epratuzumab produced clinically relevant improvements in disease activity in patients…
Abstract Number: 1606 • 2013 ACR/ARHP Annual Meeting
Overview Of The Safety Of Epratuzumab In Systemic Lupus Erythematosus
Daniel J. Wallace¹, Josep Ordi-Ros², C. Michael Neuwelt³, Kenneth Kalunian⁴, Michelle A. Petri⁵, Slawomir Jeka⁶, Ronald F. van Vollenhoven⁷, Brian Kilgallen⁸, Sabine Bongardt⁹, Caroline Gordon¹⁰ and Vibeke Strand¹¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Internal Medicine, Vall De Hebron General Hospt, Barcelona, Spain, ³East Bay Rheumatology Research Institute, San Leandro, CA, ⁴UCSD School of Medicine, La Jolla, CA, ⁵Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁶2nd University Hospital in Bydgoszcz Medical College of Nicolaus Copernicus University, Bydgoszcz, Poland, ⁷Clinical Trials Unit Department of Rheumatology, The Karolinska Institute, Stockholm, Sweden, ⁸UCB Pharma, Raleigh, NC, ⁹UCB Pharma, Brussels, Belgium, ¹⁰Rheumatology Research Group (East Wing), School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, ¹¹Adjunct, Division of Immunology / Rheumatology, Stanford University, Palo Alto, CA
Background/Purpose: The efficacy and safety of epratuzumab, a monoclonal antibody targeting CD22, has been evaluated in patients with moderate-to-severe systemic lupus erythematosus (SLE). A pooled…
Abstract Number: 1588 • 2013 ACR/ARHP Annual Meeting
Poor Adherence To Medications For Systemic Lupus Erythematosus Among U.S. Medicaid Beneficiaries
Jinoos Yazdany¹, Jun Liu², Graciela S. Alarcon³, Karen H. Costenbader⁴ and Candace H. Feldman⁵, ¹Medicine, University of California, San Francisco, San Francisco, CA, ²Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, Boston, CA, ³Medicine, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Rheumatology, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Immunosuppressive and anti-malarial drugs are the cornerstones of treatment for patients with systemic lupus erythematosus (SLE) and have been shown to improve outcomes,…
Abstract Number: 1561 • 2013 ACR/ARHP Annual Meeting
Treat-To-Target In Systemic Lupus Erythematosus: Report From the T2T/SLE Working Party
Ronald F. van Vollenhoven¹, Marta Mosca², George Bertsias³, Annegret Kuhn⁴, Kirsten Lerstrøm⁵, Josef S. Smolen⁶, David A. Isenberg⁷, Matthias Schneider⁸ and the T2T/SLE Working Party⁹, ¹Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), the Karolinska Institute, Stockholm, Sweden, ²I, Rheumatology Unit, Internal Medicine, University of Pisa, Pisa, Italy, ³Rheumatology, Clinical Immunology, and Allergy, University of Crete, Heraklion, Greece, ⁴University of Münster, Münster, Germany, ⁵Lupus Europe, Farum, Denmark, ⁶Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁷Centre for Rheumatology Research, Rayne Building, 4th Floor, Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, ⁸Department of Endocrinology, Diabetes and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany, ⁹the Karolinska Institute, Stockholm, Sweden
Background/Purpose: The principle of treating-to-target has been applied successfully to many diseases outside rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic targets and…
Abstract Number: 582 • 2013 ACR/ARHP Annual Meeting
A Real-World Survey Of Clinical Practice Among Rheumatologists and Nephrologists In The United States Reveals Differences In Care Of Non-Nephritis Systemic Lupus Erythematosus and Lupus Nephritis As Compared With American College Of Rheumatology Treatment Guidelines
Neelufar Mozaffarian¹, Steve Lobosco² and Adam Roughley², ¹AbbVie, North Chicago, IL, ²Adelphi Real World Ltd., Macclesfield, United Kingdom
Background/Purpose: Current pharmacotherapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN) includes combinations of nonsteroidal anti–inflammatory drugs (NSAIDs), antimalarials (AMs), glucocorticoids (GCs), and cytotoxic…
Abstract Number: 589 • 2013 ACR/ARHP Annual Meeting
A Survey Of Physician and Patient Satisfaction With Control Of Systemic Lupus Erythematosus and Lupus Nephritis
Neelufar Mozaffarian¹, Steve Lobosco² and Adam Roughley², ¹AbbVie, North Chicago, IL, ²Adelphi Real World Ltd., Macclesfield, United Kingdom
Background/Purpose: Patient satisfaction with disease control is an important component of overall health and well-being. Current treatment options for systemic lupus erythematosus (SLE) ±lupus nephritis…
Abstract Number: 579 • 2013 ACR/ARHP Annual Meeting
Switching Treatment Between Mycophenolate Mofetil and Azathioprine In Lupus Patients The Reasons and The Effect
Hesham Al Maimouni, Dafna D. Gladman, Dominique Ibanez and Murray B. Urowitz, Division of Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Disease activity in systemic lupus erythematosus is an important predictor of subsequent organ damage and mortality from lupus. However, the optimal agent for chronic…
Abstract Number: 1409 • 2012 ACR/ARHP Annual Meeting
A Multicentre Clinical Study of Umbilical Cord Mesenchymal Stem Cells Transplantation in Active Systemic Lupus Erythematosus
Lingyun Sun¹, Dandan Wang¹, Jing Li², Miao Zhang³, Yu Zhang⁴ and Xia Li¹, ¹Department of Rheumatology and Immunology, the Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China, ²Department of Rheumatology, Affiliated Hospital of Jiangsu University, Zhenjiang, China, ³Department of Rheumatology, Jiangsu Provincial People's Hospital, Nanjing, China, ⁴Department of Rheumatology, Subei People's Hospital of Jiangsu Province, Yangzhou, China
Background/Purpose: Umbilical cord (UC) derived mesenchymal stem cells (MSCs) have shown safety profile and therapeutic effect in severe and refractory systemic lupus erythematosus (SLE) in…
Abstract Number: 631 • 2012 ACR/ARHP Annual Meeting
Peripheral Neuropathy Due to Systemic Lupus Erythematosus (SLE) Itself: Incidence, Disease Risk Factors and Outcome
Simone Fargetti¹, Samuel K. Shinjo², Sandra G. Pasoto¹, Ana L. Calich¹, Eloisa Bonfa³ and Eduardo F. Borba¹, ¹Rheumatology Division, University of Sao Paulo, Sao Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, ³Rheumatology Division, University of São Paulo, Sao Paulo, Brazil
Background/Purpose: Peripheral neuropathy (PN) solely attributable to SLE itself is difficult to define since most of these patients are exposed to several other conditions that…
Abstract Number: 635 • 2012 ACR/ARHP Annual Meeting
Elevated Transglutaminase Levels On Microparticles From Systemic Lupus Erythematosus Patients
Leslie Harris¹, Ratnesh Chopra¹, Ann K. Rosenthal² and Mary E. Cronin³, ¹Division of Rheumatology/Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, ²Div of Rheumatology, Medical College of Wisconsin, Milwaukee, WI, ³Rheumatology, Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic Lupus Erythematosus ( SLE) is characterized by the formation of autoantibodies, and over-exuberant antigen presentation may account for some of this pathology .…
Abstract Number: 641 • 2012 ACR/ARHP Annual Meeting
Study of Anti-Müllerian Hormone and Probability of Pregnancy in 112 Systemic Lupus Erythematosus Patients Exposed or Not to Cyclophosphamide
Nathalie Morel¹, Anne Bachelot², Zeina Chakhtoura², Zahir Amoura¹, Olivier Aumaitre³, Jean-Emmanuel Kahn⁴, Du Boutin⁵, Pierre Duhaut⁶, Dominique Farge⁷, Camille Francès¹, Lionel Galicier⁸, Gaëlle Guettrot-Imbert³, Jean-Robert Harlé⁹, Olivier Lambotte¹⁰, Véronique Le Guern¹¹, Jean-Charles Piette¹², Jacques Pourrat¹³, Karim Sacre¹⁴, Damien Sene¹⁵, Salim Trad¹⁶, Elisabeth Vidal¹⁷, Lamiae Grimaldi¹⁸, Christiane Coussieu¹⁹, Nathalie Costedoat-Chalumeau²⁰ and PLUS²¹, ¹Internal Medicine, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ²Endocrinology, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ³Internal Medicine, Centre Hospitalier de Clermont-Ferrand, Clermont-Ferrand, France, ⁴Internal Medicine, Foch Hospital, Suresnes, France, ⁵Internal Medicine, Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, ⁶Internal Medicine and RECIF, CHU Nord, Amiens, France, ⁷Medicine, EBMT, Paris, France, ⁸Internal Medicine, Hopital Saint Louis, Paris, France, ⁹Internal Medicine, CHU Toulouse, Toulouse, France, ¹⁰Internal Medicine, Hopital Kremlin Bicêtre, Kremlin Bicêtre, France, ¹¹Department of Internal Medicine, Cochin Hospital, Paris, France, ¹²Internal Medicine 2, Groupe Hospitalier Pitié-Salpétrière, Paris, France, ¹³Toulouse University Hospital, University of Toulouse, Toulouse, France, ¹⁴Internal Medicine, University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, ¹⁵Internal Medicine, Hopital Lariboisière, Paris, France, ¹⁶Internal Medicine, Hopital Ambroise Paré, Paris, France, ¹⁷Department of Internal Medicine A, Dupuytren Hospital, Limoges University Hospital, Limoges, France, ¹⁸Société Laser, Paris, France, ¹⁹Groupe Hospitalier Pitié-Salpétrière, Paris, France, ²⁰Internal Medicine, Hopital Cochin, Paris, France, ²¹Paris, France
Background/Purpose: Cyclophosphamide (CYC), a drug commonly used in systemic lupus erythematosus (SLE), is associated with a risk of ovarian failure resulting in infertility. In the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].